Zhiran Medical develops implantable brain-computer interface technology based on ultra-thin flexible electrodes. The company is part of China’s invasive BCI segment, with a clinical focus on motor restoration, communication support, and neurological intervention for patients with severe motor impairment.

Its platform combines flexible implantable electrodes, an implantable signal-acquisition system, neural decoding algorithms, and electrode implantation robotics. Public materials describe applications including robotic-hand, exoskeleton, and wheelchair control for patients with spinal cord injury, high-level paralysis, or ALS, alongside communication restoration through decoding of language or handwriting-related neural signals.

Zhiran completed clinical implantation of a multi-channel invasive BCI product in 2025 and has reported plans for larger registration clinical trials in 2026. The company is positioned as a clinical-stage BCI developer building a flexible-electrode platform for high-throughput neural recording and assistive motor control.